General Mills, Inc. GIS reported third-quarter fiscal 2019 results, with earnings marking fourth straight beat. Also, sales reverted to a positive trend, after fourth consecutive top-line miss. The top and bottom lines both improved on a year-on-year basis. Further, management updated its guidance for fiscal 2019.
Highlights of the Release
The company’s adjusted earnings per share of 83 cents advanced 6% year over year on a constant-currency (cc) basis. The bottom line beat the Zacks Consensus Estimate of 69 cents. The reported earnings were fueled by an increase in adjusted operating profit, which was somewhat offset by escalated interest costs, effective tax rate and average shares outstanding.
General Mills, Inc. Price, Consensus and EPS Surprise
General Mills, Inc. Price, Consensus and EPS Surprise | General Mills, Inc. Quote
Net sales of $4,198.3 million improved 8% year over year, mainly backed by gains from Blue Buffalo. At cc, the top line rose 10% from the prior-year quarter. Also, organic sales inched up 1% from the year-ago quarter, driven by positive net price realization and mix, somewhat offset by lower volumes. The top line surpassed the Zacks Consensus Estimate of $4,177 million.
Adjusted gross margin expanded 170 basis points (bps) to 34.2%, owing to cost savings and gains from mix, net price realization and Blue Buffalo. However, these upsides were countered by higher input costs.
Adjusted operating profit of $730 depicted 25% year-over-year growth at cc, driven by improved sales and adjusted gross margin. Adjusted operating margin increased 230 bps to 17.4%.
North America Retail: Revenues in the segment came in at $2,518.6 million, flat year over year. The company witnessed growth in U.S. Cereal and U.S. Meals & Baking operating units. However, this upside was mitigated by sluggishness in Canada, U.S. Snacks and U.S. Yogurt. Organic sales in the segment recorded modest growth.
Convenience Stores & Foodservice: Revenues edged up 3% year over year to $472.5 million. Growth in Focus 6 platforms including frozen meals, baked goods, snacks and yogurt had a positive effect on the segment’s results. However, the upside was countered by weakness in bakery flour. Organically, sales rose 3% from the year-ago period.
Europe & Australia: On a year-over-year basis, the segment’s revenues declined 8% to $432.7 million due to unfavorable currency impacts. Further, sales declined 2% year over year on an organic basis. Lower sales for Yoplait yogurt and an unfavorable impact of a persistent challenging retail landscape in France led to the downside. However, the decline was somewhat offset by double-digit growth in snack bars and Haagen-Dazs ice cream.
Asia & Latin America: Revenues declined almost 2% from a year ago to $427.7 million due to unfavorable currency movements, and headwinds from the sale of La Saltena fresh pasta and refrigerated dough business in Argentina. However, sales rose 7% on an organic basis. Pillsbury, Nature Valley snack bars, Haagen-Dazs ice cream and Wanchai Ferry frozen dumplings were some of the products that performed well in the segment.
Pet Segment: Revenues came in at $346.8 million. Sales in the segment grew 4% year over year on a pro-forma basis, thanks to growth in Food, Drug, and Mass (FDM) and e-commerce channels. The growth was partly offset by declines in the Pet Specialty channel.
Other Financial Aspects
The company ended the quarter with cash and cash equivalents of $547.1 million, a long-term debt of $11,642.6 million, and total shareholder equity of $6,930.4 million.
General Mills generated $2,027.6 million as net cash from operating activities in the first nine months of the fiscal year. During this period, the company made capital investments worth $368 million.
General Mills paid dividends of roughly $884 million on a year-to-date basis.
Constant-currency sales from joint ventures of Cereal Partners Worldwide inched up 2% in the third quarter, while the same fell 5% from the prior-year period at Haagen-Dazs Japan.
Fiscal 2019 Guidance
Management anticipates Blue Buffalo's sales and segment operating profit to grow at a significant pace in the fourth quarter, thanks to distribution expansion in the FDM channel. Quarterly results from base business are likely to be hurt by year-over-year comparison, including robust quarterly performance of the last fiscal year. The company is currently focused on Consumer First strategy, cost-reduction initiatives and focus on global growth to boost sales momentum.
Driven by year-to-date performance and fourth-quarter projections, General Mills revised its guidance for fiscal 2019. Management now expects organic sales to come toward the lower end of its previous guided range of flat to up 1%. Net sales are also projected to come toward the lower end of 9-10% growth on cc basis, including the impact of Blue Buffalo’s buyout. Currency translations are expected to weigh on net sales by 1-2 percentage points.
Adjusted operating profit (on cc basis) is expected near the upper end of its earlier projected range of 6-9% growth compared with $2.6 billion recorded in fiscal 2018. The company envisions adjusted earnings per share (on cc basis) growth in the range of flat to up 1% from the fiscal 2018 figure of $3.11. Earlier, it anticipated adjusted earnings per share (on cc basis) growth in the range of 3% decline to flat.
It estimates free cash flow conversion of minimum 105% of adjusted after-tax earnings, higher than the earlier expectation of at least 95%.
This Zacks Rank #2 (Buy) company’s shares have advanced 33.1% in the past three months, outperforming the industry’s 6.6% growth.
Looking for More Consumer Staples Stocks? Check These
Medifast, Inc. MED, with an expected long-term EPS growth rate of 20%, sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
MGP Ingredients, Inc. MGPI, also a Zacks Rank #1 stock, delivered average positive earnings surprise of 2.4% in the last four quarters.
Sysco Corporation SYY, with a Zacks Rank #2 (Buy), has a long-term EPS growth rate of 10.3%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sysco Corporation (SYY) : Free Stock Analysis Report
MGP Ingredients, Inc. (MGPI) : Free Stock Analysis Report
General Mills, Inc. (GIS) : Free Stock Analysis Report
MEDIFAST INC (MED) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research